AuthorisedTherapeutic confirmatory (Phase III)Interventional

Accelerate Improvement in Multiple Myeloma for Newly Diagnosed Transplant-Eligible Patients (AugMMent)

The AugMMent study is a Phase III clinical trial for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. Researchers are testing various combinations of existing and newer medicines, such as Lenalidomid, teclistamab, VELCADE, Darzalex, and Dexamethasone, to see if they can improve treatment outcomes. The main goal is to check how well these treatments reduce the amount of cancer cells in the body, specifically looking for 'MRD negativity' before patients start their ongoing maintenance therapy. This means trying to get rid of as many cancer cells as possible. The study also looks at how long this improvement lasts and any serious side effects like infections.

At a glance

Status

Authorised

Phase

Therapeutic confirmatory (Phase III)

Sponsor

Universitaetsklinikum Heidelberg AöR

Enrolment target

399

Start

09 Jun 2026

Newly diagnosed Multiple Myeloma in patients eligible for stem cell transplantation

What is this study about?

This study, called AugMMent, is a very important research project looking into better ways to treat multiple myeloma. Multiple myeloma is a type of cancer that affects the plasma cells in the bone marrow, which are part of your immune system. If you've recently been diagnosed with multiple myeloma and your doctors think you're well enough for a stem cell transplant, this study might be relevant to you.

The main idea behind AugMMent is to see if combining several different medications can lead to a really powerful start to your treatment. The study uses medicines like Lenalidomid, teclistamab, VELCADE, Darzalex, and Dexamethasone. Some of these are established treatments for multiple myeloma, while others might be newer approaches. By trying out these combinations, doctors hope to find a way to reduce the amount of cancer cells in your body more effectively than current standard treatments.

The main thing the study is looking for is something called 'MRD negativity'. MRD stands for 'minimal residual disease', and if you're MRD negative, it means that very sensitive tests can't find any remaining myeloma cells in your bone marrow after treatment. Achieving MRD negativity before starting long-term maintenance therapy is a good sign, and researchers want to see if these new combinations can help more people reach this important goal. The study is also watching to see how long these good results last and if there are any significant side effects, especially severe infections.

Key takeaways

This study is testing new combinations of treatments for newly diagnosed multiple myeloma.
It's for people who are suitable for a stem cell transplant.
The main goal is to see if treatments can make the cancer undetectable (MRD negative).
It's a 'Phase III' study, meaning it's comparing promising treatments to see which works best.
You would receive regular check-ups and medications as part of your participation.

Who may be eligible?

To join the AugMMent study, you need to be an adult, at least 18 years old. The study is open to both men and women.

Crucially, you must have been recently diagnosed with multiple myeloma. This isn't a study for people who have had multiple myeloma for a long time or whose cancer has come back. It's specifically for those starting their initial treatment.

Another key requirement is that your doctors must consider you suitable for a stem cell transplant. This means you should be in reasonably good health overall, as a stem cell transplant is an intensive procedure.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Have you recently been diagnosed with multiple myeloma?
Has your doctor said you are well enough for a stem cell transplant?
Are you prepared to attend regular hospital appointments?

Answer every question to see your result.

What does participation involve?

Taking part in AugMMent would involve receiving a specific combination of study medications, as decided by the research team. You would have regular visits to the hospital for assessments, blood tests, and to receive your treatments. These assessments are important for the doctors to monitor your health, how effectively the treatment is working, and to keep an eye on any side effects. You would continue these treatments and follow-up appointments for a significant period. The study aims to look at how well the treatment works before you start later, ongoing maintenance therapy and will also follow your health for how long any benefits last, and to monitor for side effects, including serious infections. The total duration of your participation would be discussed in detail by the study team.

Potential risks and benefits

Taking part in a study like AugMMent could offer the potential benefit of receiving new treatment combinations that might be more effective in controlling your multiple myeloma compared to standard care. However, as with any medical treatment, there are potential risks and side effects from the medications involved. These could range from mild to severe, including the risk of serious infections. The study team will carefully monitor you for any side effects. You are always in control and have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Germany

Common questions

What is multiple myeloma?

Multiple myeloma is a cancer of plasma cells, which are a type of white blood cell found in your bone marrow. These cells help fight infections.

What does 'MRD negativity' mean?

MRD negativity means that very sensitive medical tests can't find any remaining cancer cells in your body after treatment. It's a good sign that treatment has been very effective.

What is a stem cell transplant?

A stem cell transplant is an intensive treatment sometimes used for blood cancers like multiple myeloma. It involves replacing damaged blood-forming cells with new, healthy ones.

Are the study drugs new or commonly used?

The study uses a combination of both established medications and potentially newer approaches for multiple myeloma treatment.

Will I know which treatment I'm getting?

The study team will explain the treatment plan to you in full detail as part of the consent process. It is common in studies like this for the specific combination to be determined by random allocation.